Heerfordt's syndrome
ICD-10 D86.9 · ICD-11 4B20.Y.6

First-Line Treatment of Heerfordt's Syndrome: Facial Nerve Weakness and Anterior Uveitis

Heerfordt's syndrome involves concurrent facial nerve palsy and anterior uveitis alongside parotid gland involvement. Both the neurologic and ocular components require distinct, targeted management to prevent lasting damage.

This protocol addresses the first-line approach for patients presenting with these features — with defined clinical goals for both systems.

Treatment Goals
Treatment Approach

Management is built around a corticosteroid-based strategy, combining a systemic route for neurologic involvement with a topical ophthalmic route for anterior uveitis.

Systemic corticosteroid therapy is the recommended first line for neurologic involvement, paired with specific topical agents for ocular inflammation. The complete regimen — including agents, tapering schedule, and decision criteria — is detailed in the full protocol.
Instant Access to Structured Evidence-Based Regimens
References

Corticosteroid treatment is recommended as the first line of therapy for neurologic involvement.

A limited course of prednisone 20-40 mg daily is recommended for these patients.

The dosage should be tapered over 1-6 months and can be discontinued if weakness resolves.

Anterior uveitis usually can be managed with local therapy using corticosteroid eye drops to suppress inflammation and cycloplegic eye drops to suppress pain and avoid intraocular scarring.

View source ↗